Illumina, Inc. (ILMN)

Illumina's stock price has been impacted by several key events including the Q4 2025 earnings report, muted fiscal 2026 guidance, the SomaLogic acquisition, and general stock price fluctuations. The company reported Q4 2025 earnings that exceeded market expectations, but investor sentiment soured on the company's fiscal 2026 guidance. The acquisition of SomaLogic was flagged as potentially causing a margin hit and EPS dilution. Illumina's stock has experienced a 9.21% change over the past year, with a 52-week range between $68.70 and $155.53.

Illumina has experienced subdued demand for its genetic testing tools and diagnostics products, particularly due to cautious customer spending and a protracted recovery in the China market. Research and academic demand has remained subdued, while clinical consumables have shown strong year-over-year growth. There is usual seasonality in instrument purchases, and investment needs can lead to short-term swings in free cash flow.

Illumina, Inc. is a biotechnology company specializing in genetic and genomic analysis, dedicated to improving human health through integrated systems. Its products and services include sequencing instruments, consumables, whole-genome and targeted resequencing kits, the Galleri multi-cancer early detection test, software and analysis tools, and various services like sequencing, genotyping, and consulting.

Illumina has a significant global presence, serving customers in over 155 countries across the Americas, Europe, and Asia-Pacific. The company directly markets its products in North America, Europe, Latin America, and the Asia-Pacific region, and collaborates with life-science distributors in Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Illumina's brand reputation has been affected by its placement on China's Unreliable Entity List and the GRAIL divestiture and regulatory scrutiny. China accused Illumina of violating market trading principles, causing shares to fall. Regulatory challenges and the eventual divestiture of GRAIL have also impacted Illumina's image.

Illumina, Inc. has a concentrated institutional ownership with a low percentage held by individual insiders. As of recent filings, Illumina has 1248 institutional owners and shareholders holding a total of 185,794,682 shares. Major institutional owners include Capital World Investors, BlackRock, Inc., and Vanguard Group Inc.